David D. Stenehjem

2.7k total citations · 1 hit paper
113 papers, 1.8k citations indexed

About

David D. Stenehjem is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, David D. Stenehjem has authored 113 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 26 papers in Cancer Research. Recurrent topics in David D. Stenehjem's work include Cancer Genomics and Diagnostics (20 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Treatments and Mutations (16 papers). David D. Stenehjem is often cited by papers focused on Cancer Genomics and Diagnostics (20 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Treatments and Mutations (16 papers). David D. Stenehjem collaborates with scholars based in United States, Austria and Canada. David D. Stenehjem's co-authors include Jeffrey A. Gilreath, George M. Rodgers, Alok A. Khorana, Wojtek Wiercioch, Cihan Ay, Andrew D. Leavitt, Pablo Alonso‐Coello, Gary H. Lyman, Agnes Lee and Marcello Di Nisio and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David D. Stenehjem

102 papers receiving 1.7k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

2021 489 citations Gary H. Lyman, Marc Carrier et al. Blood Advances profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David D. Stenehjem United States	18	626	438	402	318	318	113	1.8k
Chris E. Holmes United States	19	782 1.2×	365 0.8×	259 0.6×	420 1.3×	244 0.8×	58	1.8k
Xiaolei Zhu China	14	830 1.3×	235 0.5×	678 1.7×	604 1.9×	625 2.0×	35	2.1k
Ann Alexis Prestrud United States	11	685 1.1×	477 1.1×	305 0.8×	178 0.6×	348 1.1×	19	2.5k
Julie Hambleton United States	17	1.1k 1.8×	665 1.5×	598 1.5×	556 1.7×	661 2.1×	31	3.0k
Hikmat Abdel‐Razeq Jordan	17	481 0.8×	225 0.5×	195 0.5×	138 0.4×	152 0.5×	155	1.2k
Maddalena Barba Italy	34	921 1.5×	1.3k 2.9×	471 1.2×	527 1.7×	827 2.6×	118	3.3k
Maureen G. Conlan United States	30	308 0.5×	248 0.6×	764 1.9×	287 0.9×	367 1.2×	73	2.7k
Zhenguo Zhai China	22	229 0.4×	1.1k 2.5×	857 2.1×	235 0.7×	941 3.0×	188	2.3k
Hanny Al‐Samkari United States	31	461 0.7×	527 1.2×	579 1.4×	275 0.9×	293 0.9×	193	3.8k
Jamey Skillings Canada	18	1.3k 2.0×	126 0.3×	514 1.3×	281 0.9×	261 0.8×	40	2.1k

Countries citing papers authored by David D. Stenehjem

Since Specialization

Citations

This map shows the geographic impact of David D. Stenehjem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David D. Stenehjem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David D. Stenehjem more than expected).

Fields of papers citing papers by David D. Stenehjem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David D. Stenehjem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David D. Stenehjem. The network helps show where David D. Stenehjem may publish in the future.

Co-authorship network of co-authors of David D. Stenehjem

This figure shows the co-authorship network connecting the top 25 collaborators of David D. Stenehjem. A scholar is included among the top collaborators of David D. Stenehjem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David D. Stenehjem. David D. Stenehjem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jacobson, Pamala A., Jeffrey R. Bishop, Natasha Petry, et al.. (2025). Pharmacogenomics case-based education: Establishment of an Extension for Community Health Outcomes (ECHO) education model for healthcare professionals. American Journal of Health-System Pharmacy. 83(2). 102–112.

Schabath, Matthew B., Jonathan P. Thompson, Jyoti Malhotra, et al.. (2024). Clinical characteristics and treatment patterns of patients with NTRK fusion–positive solid tumors: A multisite cohort study at US academic cancer centers. Journal of Managed Care & Specialty Pharmacy. 30(7). 672–683. 1 indexed citations

Tan, Chia Jie, Anindit Chhibber, Clara Lam, et al.. (2024). Patient characteristics and treatment patterns of patients with locally advanced or metastatic HER2-low breast cancer, a single site descriptive study. Breast Cancer Research and Treatment. 208(3). 619–630.

Stenehjem, David D., Solomon J. Lubinga, Aozhou Wu, & Keith A. Betts. (2023). Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors. Journal of Managed Care & Specialty Pharmacy. 29(9). 1054–1064. 2 indexed citations

King‐Kallimanis, Bellinda L., Vishal Bhatnagar, Bindu Kanapuru, et al.. (2023). Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma. Quality of Life Research. 32(8). 2281–2292. 2 indexed citations

Korytowsky, Beata, et al.. (2023). CO95 Matching-Adjusted Indirect Comparison (MAIC) in Previously Treated KRAS G12C-Mutated Advanced/Metastatic Non-Small Cell Lung Cancer (a/mNSCLC): Adagrasib Versus Sotorasib. Value in Health. 26(12). S31–S31. 2 indexed citations

Brown, Jacob T., et al.. (2022). Perceptions of pharmacogenetic exceptionalism and the implications for clinical management within an electronic health record. Clinical and Translational Science. 15(9). 2265–2274. 1 indexed citations

Walker, Brandon S., Jennifer Ose, Christopher I. Li, et al.. (2021). Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?. Cancer Epidemiology Biomarkers & Prevention. 30(6). 1106–1113. 2 indexed citations

Stenehjem, David D., Solomon J. Lubinga, Keith A. Betts, et al.. (2021). Treatment Patterns in Patients with Metastatic Non-Small-Cell Lung Cancer in the Era of Immunotherapy. Future Oncology. 17(22). 2940–2949. 14 indexed citations

10.

Brown, Jacob T., et al.. (2021). Integrating Pharmacogenetic Testing Via Medication Therapy Management in an Outpatient Family Medicine Clinic. Pharmacogenomics. 22(4). 203–212. 6 indexed citations

11.

Lyman, Gary H., Marc Carrier, Cihan Ay, et al.. (2021). American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Advances. 5(4). 927–974. 489 indexed citations breakdown →

12.

Waring, Stephen C., et al.. (2020). Pharmacist’s attitudes and knowledge of pharmacogenomics and the factors that may predict future engagement. Pharmacy Practice. 18(3). 2008–2008. 16 indexed citations

13.

Griffiths, Jason I., Pierre Wallet, Lance Pflieger, et al.. (2020). Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy. Proceedings of the National Academy of Sciences. 117(27). 16072–16082. 67 indexed citations

14.

Stenehjem, David D., Solomon J. Lubinga, Komal Gupte-Singh, et al.. (2020). Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States. Clinical Lung Cancer. 22(1). e35–e47. 5 indexed citations

15.

Hahn, Andrew W., David D. Stenehjem, Anitha Alex, et al.. (2019). Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urologic Oncology Seminars and Original Investigations. 37(6). 352.e19–352.e24. 2 indexed citations

16.

Stenehjem, David D., Andrew W. Hahn, David Gill, et al.. (2019). Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS ONE. 14(1). e0210415–e0210415. 11 indexed citations

17.

Gilcrease, Glynn Weldon, David D. Stenehjem, Mark Wade, et al.. (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer. Investigational New Drugs. 37(3). 482–489. 17 indexed citations

18.

Hahn, Andrew W., et al.. (2018). Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer. 16(5). 365–368. 34 indexed citations

19.

Stenehjem, David D., et al.. (2018). PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy. Volume 11. 5973–5989. 102 indexed citations

20.

Jahn, Beate, Ursula Rochau, Christina Kurzthaler, et al.. (2017). Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. BMC Cancer. 17(1). 685–685. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact